Type 2 Diabetes Modifies the Association of CAD Genomic Risk Variants With Subclinical Atherosclerosis
BACKGROUND: Individuals with type 2 diabetes (T2D) have an increased risk of coronary artery disease (CAD), but questions remain about the underlying pathology. Identifying which CAD loci are modified by T2D in the development of subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness, or carotid plaque) may improve our understanding of the mechanisms leading to the increased CAD in T2D.
METHODS: We compared the common and rare variant associations of known CAD loci from the literature on CAC, carotid intima-media thickness, and carotid plaque in up to 29 670 participants, including up to 24 157 normoglycemic controls and 5513 T2D cases leveraging whole-genome sequencing data from the Trans-Omics for Precision Medicine program. We included first-order T2D interaction terms in each model to determine whether CAD loci were modified by T2D. The genetic main and interaction effects were assessed using a joint test to determine whether a CAD variant, or gene-based rare variant set, was associated with the respective subclinical atherosclerosis measures and then further determined whether these loci had a significant interaction test.
RESULTS: Using a Bonferroni-corrected significance threshold of P<1.6×10-4, we identified 3 genes (ATP1B1, ARVCF, and LIPG) associated with CAC and 2 genes (ABCG8 and EIF2B2) associated with carotid intima-media thickness and carotid plaque, respectively, through gene-based rare variant set analysis. Both ATP1B1 and ARVCF also had significantly different associations for CAC in T2D cases versus controls. No significant interaction tests were identified through the candidate single-variant analysis.
CONCLUSIONS: These results highlight T2D as an important modifier of rare variant associations in CAD loci with CAC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Circulation. Genomic and precision medicine - 16(2023), 6 vom: 01. Dez., Seite e004176 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Completed 21.12.2023 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCGEN.123.004176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365057304 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365057304 | ||
| 003 | DE-627 | ||
| 005 | 20240425232526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCGEN.123.004176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM365057304 | ||
| 035 | |a (NLM)38014529 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasbani, Natalie R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type 2 Diabetes Modifies the Association of CAD Genomic Risk Variants With Subclinical Atherosclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2023 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Individuals with type 2 diabetes (T2D) have an increased risk of coronary artery disease (CAD), but questions remain about the underlying pathology. Identifying which CAD loci are modified by T2D in the development of subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness, or carotid plaque) may improve our understanding of the mechanisms leading to the increased CAD in T2D | ||
| 520 | |a METHODS: We compared the common and rare variant associations of known CAD loci from the literature on CAC, carotid intima-media thickness, and carotid plaque in up to 29 670 participants, including up to 24 157 normoglycemic controls and 5513 T2D cases leveraging whole-genome sequencing data from the Trans-Omics for Precision Medicine program. We included first-order T2D interaction terms in each model to determine whether CAD loci were modified by T2D. The genetic main and interaction effects were assessed using a joint test to determine whether a CAD variant, or gene-based rare variant set, was associated with the respective subclinical atherosclerosis measures and then further determined whether these loci had a significant interaction test | ||
| 520 | |a RESULTS: Using a Bonferroni-corrected significance threshold of P<1.6×10-4, we identified 3 genes (ATP1B1, ARVCF, and LIPG) associated with CAC and 2 genes (ABCG8 and EIF2B2) associated with carotid intima-media thickness and carotid plaque, respectively, through gene-based rare variant set analysis. Both ATP1B1 and ARVCF also had significantly different associations for CAC in T2D cases versus controls. No significant interaction tests were identified through the candidate single-variant analysis | ||
| 520 | |a CONCLUSIONS: These results highlight T2D as an important modifier of rare variant associations in CAD loci with CAC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a atherosclerosis | |
| 650 | 4 | |a coronary artery disease | |
| 650 | 4 | |a diabCs, type 2 | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Westerman, Kenneth E |e verfasserin |4 aut | |
| 700 | 1 | |a Kwak, Soo Heon |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xihao |e verfasserin |4 aut | |
| 700 | 1 | |a Di Corpo, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Wessel, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Bis, Joshua C |e verfasserin |4 aut | |
| 700 | 1 | |a Sarnowski, Chloè |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Peitao |e verfasserin |4 aut | |
| 700 | 1 | |a Bielak, Lawrence F |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xiuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Heard-Costa, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Kinney, Gregory L |e verfasserin |4 aut | |
| 700 | 1 | |a Mahaney, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Montasser, May E |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, Nicholette D |e verfasserin |4 aut | |
| 700 | 1 | |a Raffield, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Terry, James G |e verfasserin |4 aut | |
| 700 | 1 | |a Yanek, Lisa R |e verfasserin |4 aut | |
| 700 | 1 | |a Bon, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Bowden, Donald W |e verfasserin |4 aut | |
| 700 | 1 | |a Brody, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Duggirala, Ravindranath |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyani, Rita R |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Leslie A |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Braxton D |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Kent D |e verfasserin |4 aut | |
| 700 | 1 | |a Carson, April P |e verfasserin |4 aut | |
| 700 | 1 | |a Curran, Joanne E |e verfasserin |4 aut | |
| 700 | 1 | |a Fornage, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Freedman, Barry I |e verfasserin |4 aut | |
| 700 | 1 | |a Gabriel, Stacey |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Namrata |e verfasserin |4 aut | |
| 700 | 1 | |a Kardia, Sharon L R |e verfasserin |4 aut | |
| 700 | 1 | |a Kral, Brian G |e verfasserin |4 aut | |
| 700 | 1 | |a Momin, Zeineen |e verfasserin |4 aut | |
| 700 | 1 | |a Newman, Anne B |e verfasserin |4 aut | |
| 700 | 1 | |a Post, Wendy S |e verfasserin |4 aut | |
| 700 | 1 | |a Viaud-Martinez, Karine A |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Kendra A |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Lewis C |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Alain G |e verfasserin |4 aut | |
| 700 | 1 | |a Blangero, John |e verfasserin |4 aut | |
| 700 | 1 | |a Carr, John J |e verfasserin |4 aut | |
| 700 | 1 | |a Pratte, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Psaty, Bruce M |e verfasserin |4 aut | |
| 700 | 1 | |a Rich, Stephen S |e verfasserin |4 aut | |
| 700 | 0 | |a NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; TOPMed Atherosclerosis Working Group; TOPMed Diabetes Working Group |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Joseph C |e verfasserin |4 aut | |
| 700 | 1 | |a Malhotra, Rajeev |e verfasserin |4 aut | |
| 700 | 1 | |a Peyser, Patricia A |e verfasserin |4 aut | |
| 700 | 1 | |a Morrison, Alanna C |e verfasserin |4 aut | |
| 700 | 1 | |a Vasan, Ramachandran S |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xihong |e verfasserin |4 aut | |
| 700 | 1 | |a Rotter, Jerome I |e verfasserin |4 aut | |
| 700 | 1 | |a Meigs, James B |e verfasserin |4 aut | |
| 700 | 1 | |a Manning, Alisa K |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Paul S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Genomic and precision medicine |d 2018 |g 16(2023), 6 vom: 01. Dez., Seite e004176 |w (DE-627)NLM280989210 |x 2574-8300 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:6 |g day:01 |g month:12 |g pages:e004176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCGEN.123.004176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 6 |b 01 |c 12 |h e004176 | ||